SCHEMBL7432164

SCHEMBL7432164

[CH2]CN1CCN(c2ncccn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
KDM4E B2RXH2 3/20 0.53
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
ALDH1A1 P00352 4/20 0.51
POLB P06746 1/20 0.51
TSHR P16473 1/20 0.51
HSD17B10 Q99714 1/20 0.49
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652648 0.84 HTR1A (0.55) MEN1KMT2AKDM4E
SCHEMBL10498542 0.82 LMNA (0.70) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL6663539 0.82
SCHEMBL2024052 0.81 HTR1A (0.56)
SCHEMBL9557902 0.80 HTR1A (0.58) ALDH1A1
SCHEMBL2633644 0.79 MEN1 (0.54) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL6292618 0.78 TMEM97 (0.51) MEN1KMT2A
SCHEMBL26492991 0.78 HTR1A (0.65) ALDH1A1
SCHEMBL26108581 0.78 HTR1A (0.65) ALDH1A1
SCHEMBL7297746 0.77 POLB (0.59) KDM4EMAPTALDH1A1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012050884-A2 CARDIAC GLYCOSIDES ARE POTENT INHIBITORS OF INTERFERON-BETA GENE EXPRESSION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-04-19 WO claimed
US-5580871-A FOR TREATMENT OF CONGESTIVE HEART FAILURE THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-03 US claimed
EP-0475187-A1 Naphthothiophenimines for treating neuronal disorders caused by ischemia BRISTOL-MYERS SQUIBB COMPANY (US) 1992-03-18 EP claimed
US-5064831-A N-methyl-d-aspartate receptor antagonist BRISTOL-MYERS SQUIBB CO. (US) 1991-11-12 US claimed
US-20220054499-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2022-02-24 US disclosed
US-11026952-B2 Small molecules for mouse satellite cell proliferation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2021-06-08 US disclosed
US-10660902-B2 Method of increasing satellite cell proliferation with an HDAC inhibitor PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2020-05-26 US disclosed
EP-3411040-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION President and Fellows of Harvard College (US) 2018-12-12 EP disclosed
US-20180153902-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION HOWARD HUGHES MEDICAL INSTITUTE 2018-06-07 US disclosed
WO-2017136480-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-08-10 WO disclosed
EP-2646107-A2 AGENT DELIVERY SYSTEMS FOR SELECTIVE NEUROMODULATION Spinal Modulation Inc. (US) 2013-10-09 EP disclosed
WO-2012174537-A2 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-12-20 WO disclosed
WO-2012075337-A2 DIRECTED DELIVERY OF AGENTS TO NEURAL ANATOMY SPINAL MODULATION, INC. (US) 2012-06-07 WO disclosed
WO-2012050884-A2 CARDIAC GLYCOSIDES ARE POTENT INHIBITORS OF INTERFERON-BETA GENE EXPRESSION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-04-19 WO disclosed
US-5580871-A FOR TREATMENT OF CONGESTIVE HEART FAILURE THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1996-12-03 US disclosed
US-5432188-A Treating congestive heart failure THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-07-11 US disclosed
US-5215967-A AMINOACID DERIVATIVES INHIBITING RENIN MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1993-06-01 US disclosed
US-5166147-A Congestive heart failure THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-11-24 US disclosed
US-5064831-A N-methyl-d-aspartate receptor antagonist BRISTOL-MYERS SQUIBB CO. (US) 1991-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11026952-B2 Small molecules for mouse satellite cell proliferation MKI67, MYLK2, MYH2 MEN1 4412/4885KMT2A 1908/4885KDM4E 1110/4885
US-10660902-B2 Method of increasing satellite cell proliferation with an HDAC inhibitor HDAC4, HDAC1, HDAC5 MEN1 4576/4885KMT2A 86/4885KDM4E 150/4885
US-20220054499-A1 SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 MEN1 4412/4885KMT2A 1908/4885KDM4E 1110/4885
US-20180153902-A1 SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION MKI67, MYLK2, MYH2 MEN1 4381/4885KMT2A 1776/4885KDM4E 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.